^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Leukeran (chlorambucil)

    Company:
    Aspen Pharma, GSK
    Drug class:
    Alkylating agent
    Related drugs:
    Apply
    Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL (ELEVATE-TN) (NCT02475681)
    Phase 3
    Acerta Pharma BV
    Active, not recruiting
    Last update posted :
    05/29/2024
    Initiation :
    06/26/2015
    Primary completion :
    02/08/2019
    Completion :
    09/30/2025
    CD20 • CD5 • FCER2
    |
    Gazyva (obinutuzumab) • Calquence (acalabrutinib) • Leukeran (chlorambucil)
    Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) (NCT04692740)
    Phase 2
    Michele Reni
    Active, not recruiting
    Last update posted :
    09/21/2023
    Initiation :
    12/18/2020
    Primary completion :
    01/04/2023
    Completion :
    12/01/2023
    BRCA1 • BRCA2 • HRD
    |
    BRCA2 mutation • BRCA1 mutation • HRD • HRD + BRCA1 mutation
    |
    Leukeran (chlorambucil)
    Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma (NCT01808599)
    Phase 2
    International Extranodal Lymphoma Study Group (...
    Active, not recruiting
    Last update posted :
    05/18/2023
    Initiation :
    12/01/2013
    Primary completion :
    03/01/2016
    Completion :
    09/01/2028
    CD20
    |
    CD20 positive
    |
    Leukeran (chlorambucil) • Rituxan Hycela (rituximab/hyaluronidase)
    Gazyva Infusion Reaction Investigation (GAIRI) (NCT03529227)
    Phase N/A
    Healthy Future
    Recruiting
    Last update posted :
    02/14/2022
    Initiation :
    03/31/2018
    Primary completion :
    08/31/2024
    Completion :
    04/30/2025
    CD20
    |
    Gazyva (obinutuzumab) • Leukeran (chlorambucil)
    A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (iLLUMINATE ) (NCT02264574)
    Phase 3
    Pharmacyclics LLC.
    Completed
    Last update posted :
    09/21/2020
    Initiation :
    10/06/2014
    Primary completion :
    03/26/2018
    Completion :
    09/03/2019
    TP53 • IGH
    |
    TP53 mutation • Chr del(11q) • TP53 mutation + Chr del(17p) • IGH mutation
    |
    Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Leukeran (chlorambucil)
    A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia (NCT01905943)
    Phase 3
    Hoffmann-La Roche
    Completed
    Last update posted :
    10/28/2019
    Initiation :
    11/04/2013
    Primary completion :
    12/29/2016
    Completion :
    10/08/2018
    TP53
    |
    TP53 mutation
    |
    Gazyva (obinutuzumab) • cyclophosphamide • bendamustine • Leukeran (chlorambucil) • fludarabine IV • cyclophosphamide intravenous
    Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma (NCT00210353)
    Phase 3
    International Extranodal Lymphoma Study Group (...
    Completed
    Last update posted :
    06/06/2019
    Initiation :
    01/01/2003
    Primary completion :
    04/01/2015
    Completion :
    02/17/2016
    CD20
    |
    CD20 positive
    |
    Rituxan (rituximab) • Leukeran (chlorambucil)